MedTrace Logo

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCT01655680 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 432

Last updated 2021-07-07

No results posted yet for this study

Summary

This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.

Conditions

Interventions

DRUG

ABT-126

ABT-126 Middle Dose

DRUG

ABT-126

ABT-126 Low Dose

DRUG

ABT-126

ABT-126 High Dose

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • George Haig, PharmD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-04-30
Completion
2014-07-31

Countries

  • United States
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01655680 on ClinicalTrials.gov